CHD is a historically strong compounder, but recent results show flat or negative growth, and management has cut guidance for 2025. Despite strong execution and brands, domestic sales have stalled, ...
Church & Dwight is upgraded from 'sell' to 'hold' after robust Q3 2025 results and improved operational momentum. CHD outperformed peers with 5% revenue growth, strong volume and pricing, and raised ...
Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results